Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
In the last 90 days, Lineage Cell Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 143 institutions reported holding it in 13F filings for Q3 2026, worth $112.0M in total; no superinvestor holds it.
Holders of 5% or more of LCTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lineage Cell Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Broadwood Partners, L.P. | 13D/A | 23.10%57.8M shares | −1.40 ppfrom 24.50% | Mar 16, 20216 filings | Nov 14, 2025 | SEC |
| BlackRock, Inc. | 13G | 5.30%13.2M shares | +4.30 ppfrom 1.00% | Oct 22, 20246 filings | Jul 29, 2026 | SEC |
| Chernett Jorey | 13G | 5.00%11.4M shares | New | Sep 26, 20251 filing | Sep 26, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
15 Schedule 13D and 13G filings on Lineage Cell Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 29, 20263:19 PM ET | BlackRock, Inc. | 13G | 5.30%13.2M shares | +4.30 ppfrom 1.00% | Jun 30, 2026 | SEC |
| Nov 14, 20256:12 PM ET | Broadwood Partners, L.P.and 2 others | 13D/A | 23.10%57.8M shares | −1.40 ppfrom 24.50% | Nov 12, 2025 | SEC |
| Sep 26, 202511:52 AM ET | Chernett Jorey | 13G | 5.00%11.4M shares | New | Sep 22, 2025 | SEC |
| Jul 17, 20257:54 PM ET | BlackRock, Inc. | 13G/A | 1.00%2.23M shares | −4.00 ppfrom 5.00%Below 5% | Jun 30, 2025 | SEC |
| Apr 24, 20258:48 AM ET | BlackRock, Inc. | 13G | 5.00%11.5M shares | +0.40 ppfrom 4.60% | Mar 31, 2025 | SEC |
| Feb 5, 20255:28 PM ET | BlackRock, Inc. | 13G/A | 4.60%10.1M shares | –Below 5% | Dec 31, 2024 | SEC |
| Jan 28, 20258:07 PM ET | Broadwood Partners, L.P.and 2 others | 13D/A | 24.50%57.8M shares | – | Jan 27, 2025 | SEC |
| Nov 21, 2024 | Broadwood Partners, L.P. | 13D/AOld format | – | – | – | SEC |
| Nov 8, 2024 | BlackRock, Inc. | 13GOld format | – | – | – | SEC |
| Oct 22, 2024 | BlackRock, Inc. | 13GOld format | – | New | – | SEC |
| Feb 8, 2024 | Broadwood Partners, L.P. | 13D/AOld format | – | – | – | SEC |
| Jul 8, 20224:57 PM ET | BlackRock Inc. | 13GOld format | – | – | – | SEC |
| Mar 25, 2022 | Broadwood Partners, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 4, 20224:12 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Mar 16, 2021 | Broadwood Partners, L.P. | 13D/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
2 notices from officers, directors and other affiliates planning to sell Lineage Cell Therapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 20254:39 PM ET | Don M BaileyDirector | 60.0K | $96.0K | Sep 24, 2025 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Sep 10, 20255:31 PM ET | Don M BaileyDirector | 80.0K | $97.5K | Sep 10, 2025 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |